Who was studied, and how
Five numbers in the abstract
Where each one falls
Where it lands on the map
What it changes
Among 23 other studies
190people in the Efficacy, Safety & Tolerability of Combination of Ertugliflozin and Sitagliptin in Patients With Type II Diabetes Mellitus trial, from 2022
of them with hypertension, in this paper
Among individuals with type 2 diabetes mellitus, the trial randomly assignedassigned by chance
SGLT2
control (implied)
May have lowered diastolic BP−1.46
May have lowered body weight−1.88
May have lowered serum triglycerides−2.08
randomised · one subgroupthe abstract, start to end
… for the effect on diastolic BP was -1.46 mm Hg (95% CI -1.82 to -1.09).
… the effect of SGLT2 on body weight was -1.88 kg (95% CI -2.11 to -1.66) …
… triglycerides and total cholesterol were -2.08 mg/dL (95% CI -2.51 to -1.64) and 0.77 mg/dL (95% CI 0.33-1.21), …
… with SGLT2 (weighted mean difference -2.46 mm Hg [95% CI -2.86 to -2.06]).
← favours treatmentfavours comparator →
could be chanceDiastolic BPSGLT2 vs control (implied), in individuals with type 2 diabetes mellitus
−1.46−1.82 to −1.09
Body weightSGLT2 vs control (implied), in individuals with type 2 diabetes mellitus
−1.88−2.11 to −1.66
Serum triglyceridesSGLT2 vs control (implied), in individuals with type 2 diabetes mellitus
−2.08−2.51 to −1.64
Systolic BPSGLT2 vs control (implied), in individuals with type 2 diabetes mellitus
−2.46−2.86 to −2.06
Total cholesterolSGLT2 vs control (implied), in individuals with type 2 diabetes mellitus
0.770.33–1.21
SGLT2 inhibitorsBody weight & compositionLipidsBlood pressure
SGLT2 inhibitors × blood pressurehelps?settled
unlikelylikely
0.88not counted
SGLT2 inhibitors × lipidshelps?replicated
unlikelylikely
1.00not counted
SGLT2 inhibitors × body weight & compositionhelps?settled
unlikelylikely
0.98not counted
← favours treatmentfavours comparator →
1 / 6